“amgen” Archives

in
Entry Author Date Location
Bio Roundup: Zolgensma Watch, Brain Cancer Blues, Peloton Payout & More 05/24/19 National
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms 05/20/19 New York
ASCO Abstracts: Breast Cancer, Precision Treatments in the Spotlight 05/16/19 National
SMA, Migraine Data Lead Neuro Highlights from AAN Meeting 05/07/19 National
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments 05/03/19 National
Teva’s Approved Migraine Drug Fails Again to Blunt Rarer Headache 04/23/19 New York
Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More 04/19/19 National
Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More 04/05/19 National
Bio Roundup: Pharma in DC, Bristol-Cel in Trouble, Roche Gets A Spark 03/01/19 National
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans 02/12/19 National
AbbVie Joins Myeloma Race with $90M Deal for Rights to Teneobio Drug 02/11/19 San Francisco
Matching Amgen, Regeneron to Cut List Price of Heart Drug by 60% 02/11/19 New York
Bio Roundup: Aimmune Drama, Shutdown Blues, Perlmutter Talks Cancer 01/18/19 National
FDA Panel Backs Amgen Bone Drug, Says Benefits Outweigh Heart Risks 01/16/19 National
Merck And The Future of Immuno-Oncology: A Chat With Roger Perlmutter 01/16/19 National
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More 01/11/19 National
From Alnylam to Zayner: Xconomy’s Top Innovation Stories of 2018 12/27/18 National
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
15 for ’19: Key Clinical Data to Watch for Next Year (Part 1) 12/17/18 National
Moderna Raises $604M and Nails Down Biotech’s Biggest IPO Ever 12/06/18 Boston
BCMA Day: At ASH ‘18, Cell Therapies For Myeloma Take Center Stage 12/04/18 National
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More 11/26/18 National
Eyeing $500M, Moderna Outlines Plans for Biotech’s Biggest IPO Ever 11/09/18 Boston
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel 11/09/18 National
Amgen Picks Provention to Continue Development of Celiac Disease Drug 11/05/18 New York
89Bio Joins NASH Chase with a Teva Drug and $60M in Funding 10/25/18 San Francisco
Amgen Slashes Cholesterol Drug Price 60% to Match Rival Regeneron 10/24/18 National
Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive’s End 10/19/18 National
Report: Express Scripts Shuts Out Teva Migraine Drug, Prefers Rivals 10/17/18 National
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More 10/05/18 National
Page 1 of 20 next page »